The European Journal of Health Economics

, Volume 19, Issue 2, pp 229–240 | Cite as

Cost-effectiveness of vedolizumab compared with infliximab, adalimumab, and golimumab in patients with ulcerative colitis in the United Kingdom

  • Michele R. Wilson
  • Annika Bergman
  • Helene Chevrou-Severac
  • Ross Selby
  • Michael Smyth
  • Matthew C. Kerrigan
Original Paper

Abstract

Objective

To examine the clinical and economic impact of vedolizumab compared with infliximab, adalimumab, and golimumab in the treatment of moderately to severely active ulcerative colitis (UC) in the United Kingdom (UK).

Methods

A decision analytic model in Microsoft Excel was used to compare vedolizumab with other biologic treatments (infliximab, adalimumab, and golimumab) for the treatment of biologic-naïve patients with UC in the UK. Efficacy data were obtained from a network meta-analysis using placebo as the common comparator. Other inputs (e.g., unit costs, adverse-event disutilities, probability of surgery, mortality) were obtained from published literature. Costs were presented in 2012/2013 British pounds. Outcomes included quality-adjusted life-years (QALYs). Costs and outcomes were discounted by 3.5% per year. Incremental cost-effectiveness ratios were presented for vedolizumab compared with other biologics. Univariate and multivariate probabilistic sensitivity analyses were conducted to assess model robustness to parameter uncertainty.

Results

The model predicted that anti-tumour necrosis factor-naïve patients on vedolizumab would accrue more QALY than patients on other biologics. The incremental results suggest that vedolizumab is a cost-effective treatment compared with adalimumab (incremental cost-effectiveness ratio of £22,735/QALY) and dominant compared with infliximab and golimumab. Sensitivity analyses suggest that results are most sensitive to treatment response and transition probabilities. However, vedolizumab is cost-effective irrespective of variation in any of the input parameters.

Conclusions

Our model predicted that treatment with vedolizumab improves QALY, increases time in remission and response, and is a cost-effective treatment option compared with all other biologics for biologic-naïve patients with moderately to severely active UC.

Keywords

Ulcerative colitis Vedolizumab Cost-effectiveness Economics Inflammatory bowel disease 

JEL Classification

I (Health, Education, and Welfare) 

Notes

Compliance with ethical standards

Conflict of interest

The research presented in this manuscript was funded by Takeda Pharmaceuticals, AG. Ms. Bergman, Ms. Chevrou-Severac, Mr. Selby, and Dr. Smyth are employees of Takeda. Dr. Kerrigan is an employee of PHMR Associates, a contract research organization that received funding from Takeda to conduct the analyses. Mr. Wilson is an employee of RTI Health Solutions, a contract research organization that received funding from Takeda to conduct the analyses.

Source of funding

The research presented in this manuscript was funded by Takeda Pharmaceuticals, AG.

References

  1. 1.
    Baumgart, D.C., Sandborn, W.J.: Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet 369(9573), 1641–1657 (2007)CrossRefPubMedGoogle Scholar
  2. 2.
    National Institute for Health and Care Excellence (NICE). Clinical guidelines CG166: ulcerative colitis. https://www.nice.org.uk/guidance/cg166/chapter/introduction (2010). Accessed 29 August 2013
  3. 3.
    Rubin, D.T., Dubinsky, M.C., Panaccione, R., Siegel, C.A., Binion, D.G., Kane, S.V., et al.: The impact of ulcerative colitis on patients’ lives compared to other chronic diseases: a patient survey. Dig. Dis. Sci. 55(4), 1044–1052 (2010)CrossRefPubMedGoogle Scholar
  4. 4.
    Cohen, R.D., Yu, A.P., Wu, E.Q., Xie, J., Mulani, P.M., Chao, J.: Systematic review: the costs of ulcerative colitis in Western countries. Aliment. Pharmacol. Ther. 31(7), 693–707 (2010)CrossRefPubMedGoogle Scholar
  5. 5.
    Kornbluth, A., Sachar, D.B.: Practice Parameters Committee of the American College of Gastroenterology. Ulcerative colitis practice guidelines in adults: American College of Gastroenterology, Practice Parameters Committee. J. Gastroenterol. 105(3), 501–523 (2010)Google Scholar
  6. 6.
    National Institutes of Health. Ulcerative colitis. http://www.nlm.nih.gov/medlineplus/ulcerativecolitis.html (2010). Accessed 4 Sept 2012
  7. 7.
    Rutgeerts, P., Sandborn, W.J., Feagan, B.G., Reinisch, W., Olson, A., Johanns, J., et al.: Infliximab for induction and maintenance therapy for ulcerative colitis. N. Engl. J. Med. 353(23), 2462–2476 (2005)CrossRefPubMedGoogle Scholar
  8. 8.
    Reinisch, W., Sandborn, W.J., Hommes, D.W., D’Haens, G., Hanauer, S., Schreiber, S., et al.: Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut 60(6), 780–787 (2011)CrossRefPubMedGoogle Scholar
  9. 9.
    Sandborn, W.J., Feagan, B.G., Marano, C., Zhang, H., Strauss, R., Johanns, J., et al.: Subcutaneous golimumab induces clinical response and remission in patients with moderate to severe ulcerative colitis. Gastroenterology 146(1), 85–95 (2014)CrossRefPubMedGoogle Scholar
  10. 10.
    Sandborn, W.J., Van, A.G., Reinisch, W., Colombel, J.F., D’Haens, G., Wolf, D.C., et al.: Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 142(2), 257–265 (2012)CrossRefPubMedGoogle Scholar
  11. 11.
    Loftus, E.V., Delgado, D.J., Friedman, H.S., Sandborn, W.J.: Colectomy and the incidence of postsurgical complications among ulcerative colitis patients with private health insurance in the US. Am. J. Gastroenterol. 103, 1737–1745 (2008)CrossRefPubMedGoogle Scholar
  12. 12.
    Buchanan, J., Wordsworth, S., Ahmad, T., Perrin, A., Vermeire, S., Sans, M., et al.: Managing the long term care of inflammatory bowel disease patients: the cost to European health care providers. J. Crohns Colitis. 5(4), 301–316 (2011)CrossRefPubMedGoogle Scholar
  13. 13.
    Feagan, B.G., Rutgeerts, P., Sands, B.E., Hanauer, S., Colombel, J.F., Sandborn, W.J., et al.: Vedolizumab as induction and maintenance therapy for ulcerative colitis. N. Engl. J. Med. 369(8), 699–710 (2013)CrossRefPubMedGoogle Scholar
  14. 14.
    Sandborn, W., Sands, B., Rutgeerts, P., Sankoh, S., Rosario, M., Milch, C., et al.: Sustained therapeutic benefit of vedolizumab throughout one year in ulcerative colitis in GEMINI I, a randomized, placebo-controlled, double-blind, multicenter trial. J. Crohns Colitis. 7, S138–S139 (2013)CrossRefGoogle Scholar
  15. 15.
    Tsai, H.H., Punekar, Y.S., Morris, J., Fortun, P.: A model of the long-term cost effectiveness of scheduled maintenance treatment with infliximab for moderate-to-severe ulcerative colitis. Aliment. Pharmacol. Ther. 28(10), 1230–1239 (2008)CrossRefPubMedGoogle Scholar
  16. 16.
    Ling, C., Colosia, A., Vickers, A., Ainsworth, C.: Systematic literature review and network meta-analysis in ulcerative colitis. Revised final report. (Takeda data on file, 31 Jan 2014)Google Scholar
  17. 17.
    Suzuki, Y., Motoya, S., Hanai, H., Matsumoto, T., Hibi, T., Robinson, A.M., et al.: Efficacy and safety of adalimumab in Japanese patients with moderately to severely active ulcerative colitis. J. Gastroenterol. 49(2), 283–294 (2014)CrossRefPubMedGoogle Scholar
  18. 18.
    Office for National Statistics: Death registrations summary tables, England and Wales 2010. http://www.ons.gov.uk/ons/publications/re-reference-tables.html?edition=tcm%3A77-227638 (2011). Accessed 12 Feb 2012
  19. 19.
    Jess, T., Gamborg, M., Munkholm, P., Sorensen, T.I.A.: Overall and cause-specific mortality in ulcerative colitis: meta-analysis of population-based inception cohort studies. Am. J. Gastroenterol. 102(3), 609–617 (2007)CrossRefPubMedGoogle Scholar
  20. 20.
    Royal College of Physicians: National clinical audit of biological therapies: UK inflammatory bowel disease (IBD) audit. http://www.rcplondon.ac.uk/sites/default/files/national_clinical_audit_report_of_biological_therapies_-_adult_report._29_august_2013.pdf (2013). Accessed 29 Aug 2013
  21. 21.
    Department of Health: NHS reference costs 2011–12. https://www.gov.uk/government/publications/nhs-reference-costs-financial-year-2011-to-2012 (2013). Accessed April 2016
  22. 22.
    Brown, R.E., Hutton, J., Burrell, A.: Cost effectiveness of treatment options in advanced breast cancer in the UK. Pharmacoeconomics 19(11), 1091–1102 (2001)CrossRefPubMedGoogle Scholar
  23. 23.
    Porco, T.C., Lewis, B., Marseille, E., Grinsdale, J., Flood, J., Royce, S.E.: Cost-effectiveness of tuberculosis evaluation and treatment of newly-arrived immigrants. BMC Public Health 6, 157 (2006)CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Beusterien, K.M., Davies, J., Leach, M., Meiklejohn, D., Grinspan, J., O’Toole, A., et al.: Population preference values for treatment outcomes in chronic lymphocytic leukaemia: a cross-sectional utility study. Health Qual. Life Outcomes 8, 50 (2010)CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Beusterien, K.M., Szabo, S.M., Kotapati, S., Mukherjee, J., Hoos, A., Hersey, P., et al.: Societal preference values for advanced melanoma health states in the UK and Australia. Br. J. Cancer 101(3), 387–389 (2009)CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Final Clinical Study Report C13006: A phase 3, randomized, placebo-controlled, blinded, multicenter study of the induction and maintenance of clinical response and remission by vedolizumab (MLN0002) in patients with moderate to severe ulcerative colitis (September 2012)Google Scholar
  27. 27.
    Punekar, Y., Hawkins, N.: Cost-effectiveness of infliximab for the treatment of acute exacerbations of ulcerative colitis. Eur. J. Health Econ. 11(1), 67–76 (2010)CrossRefPubMedGoogle Scholar
  28. 28.
    British National Formulary. No. 66. 2013. http://www.bnf.org/bnf/go?bnf/current/December (2013). Accessed April 2016
  29. 29.
    Curtis, L.: Unit costs of health and social care 2012. http://www.pssru.ac.uk/archive/pdf/uc/uc2012/full-with-covers.pdf. Accessed 16 Dec 2013
  30. 30.
    Frolkis, A.D., Dykeman, J., Negrón, M.E., deBruyn, J., Jette, N., Fiest, K.M., et al.: Risk of surgery for inflammatory bowel diseases has decreased over time: a systematic review and meta-analysis of population-based studies. Gastroenterology 145(5), 996–1006 (2013)CrossRefPubMedGoogle Scholar
  31. 31.
    Xie, F., Blackhouse, G., Assai, N., Gaebel, K., Rovertson, D., Goeree, R.: Cost-utility analysis of infliximab and adalimumab for refractory ulcerative colitis. Cost. Eff. Resour. Alloc. 7, 20 (2009)CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Essat, M., Tappenden, P., Ren, S., Bessey, A., Archer, R., Wong, R., Lobo, A., Hoque, S.: Vedolizumab for the treatment of adults with moderate-to-severe active ulcerative colitis: an evidence review group perspective of a NICE single technology appraisal. Pharmacoeconomics 34(3), 245–257 (2016)CrossRefPubMedGoogle Scholar
  33. 33.
    Yokomizo, L., Limketkai, B., Park, K.T.: Cost-effectiveness of adalimumab, infliximab, or vedolizumab as first-line biological therapy in moderate-to-severe ulcerative colitis. BMJ Open Gastro. 3(1), e000093 (2016)CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2017

Authors and Affiliations

  • Michele R. Wilson
    • 1
  • Annika Bergman
    • 2
  • Helene Chevrou-Severac
    • 2
  • Ross Selby
    • 3
  • Michael Smyth
    • 4
  • Matthew C. Kerrigan
    • 5
  1. 1.RTI Health SolutionsResearch Triangle ParkUSA
  2. 2.Takeda Pharmaceuticals AGZurichSwitzerland
  3. 3.Takeda UK Ltd.BucksUK
  4. 4.Takeda Development Centre Europe Ltd.LondonUK
  5. 5.PHMR LimitedLondonUK

Personalised recommendations